NEW YORK, — The federal court overseeing thousands of Xarelto bleeding lawsuits will convene a hearing on January 30, 2018 to address the future of the massive litigation.
According to an Order issued in the U.S. District Court, Eastern District of Louisiana, on December 18, 2017, the parties are to submit joint briefs by January 15th summarizing their proposals as to how federally-filed Xarelto lawsuits should proceed in the wake of the litigation’s first bellwether trials. Responses to those proposals must be filed with the Court by January 25, 2018.
Oral arguments on the matter will be heard immediately following the litigation’s January 30th Status Conference, which is scheduled to begin at 9:00 a.m. (In Re: Xarelto Products Liability Litigation, No. 2592)
“Our firm is representing a number of Xarelto lawsuit plaintiffs, and we continue to receive inquires from individuals who allegedly suffered episodes of uncontrollable internal bleeding while using this blood thinner. We look forward to the January 30th hearing, and will continue to monitor the federal litigation closely for any developments that could impact our clients’ cases,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.
Xarelto Bleeding Litigation
Xarelto is a new-generation blood thinner that was initially approved by the U.S. Food & Drug Administration in October 2011. It is currently indicated for the prevention of strokes in people with atrial fibrillation; the treatment of patients suffering from deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in people undergoing hip or knee implant surgery.
Bayer and Johnson & Johnson have been named defendants in more than 20,000 Xarelto lawsuits now pending in state and federal courts around the U.S. All of these claims were filed on behalf of patients who allegedly suffered gastrointestinal hemorrhage, cerebral hemorrhage, hemorrhagic strokes and other episodes of life-threatening internal bleeding due to its use.
Among other things, plaintiffs allege that the Bayer and Johnson & Johnson downplayed Xarelto’s risks and wrongly marketed it as an improvement over a decades-old blood thinner called warfarin. Xarelto lawsuits point out that warfarin-related bleeding can be stopped via the administration of vitamin K. However, there is currently no approved antidote to reverse Xarelto bleeding side effects.
More than 19,000 Xarelto lawsuits have been filed in the federal multidistrict litigation underway in the Eastern District of Louisiana. The proceeding convened three bellwether trials in 2017, all of which concluded with defense verdicts.
Last month, however, a jury in the Philadelphia Court of Common Please awarded $28 million, including $1.8 million in actual damages and $26 million in punitive damages, to an Indiana woman who suffered a severe gastrointestinal bleed a little over a year after she was prescribed Xarelto.
Xarelto patients who allegedly experienced bleeding side effects while using this medication may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal’s “Plaintiffs’ Hot List,” recognizing the top plaintiffs firms in the country. This year’s nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/
https://plus.google.com/115936073311125306742?rel=author